BioInformant

Your Global Leader in Stem Cell Market Research

Home » twitter

Analyzing the Mesenchymal Stem Cell (MSC) Market Using Social Analytics

By

Twitter Metrics for BioInformant - @StemCellMartketOne of the ways to use market intelligence to analyze trends within the mesenchymal stem cell (MSC) market is to assess how the cell type is being discussed on leading social media platforms, such as Twitter.

Twitter.com is one of the most widely used social media platforms today. It has with 316 million monthly active users and 500 million Tweets sent per day, according to Twitter’s company statistics. 

It is also the 9th most visited website in the world, an impressive accomplishment.

Social Analytics Reveal Key Trends about Mesenchymal Stem Cell (MSC) Research

The figure below shows a hashtag map for the term “#mesenchymal.” It was produced using the  social analytics platform Hashtagify.me.

The linked topics shown as spokes in this figure represent the top hashtags that are used together with the hashtag “#mesenchymal” on Twitter.
[Read more…]

Top Five Mesenchymal Stem Cell (MSC) Influencers on Twitter

By

This post identifies the top five mesenchymal stem cell (MSC) influencers on Twitter. This assessment was conducted using the social analytics platform Topsy.com and the hashtag “#mesenchymal”.

As you can see from the figure below, the first place Twitter account is “MesenchymalCellNews” (@mesenchymal_cell), which self-describes itself as the “online resource for the mesenchymal cell community.”  Interestingly, the second place Twitter account is “Cord Blood News” (@cord_blood_news). This account holder appears to be posting about topics pertaining to both cord blood and cord tissue, as MSCs are prevalent in large quantities in cord tissue, also called Wharton’s Jelly. Of course, I am pleased to have our account, “BioInformant” (@StemCellMarket), appear third on this list, because our Twitter feed is dedicated to posts about stem cell industry trends. [Read more…]

Massive Expansion in 2016

By

My team and I just finished an awesome planning session for 2016. We spent eight hours masterminding about how to expand in 2016, so that we can better serve our clients, partners, and readers.

Have you done your 2016 planning yet?

Whether or not you have, I suggest that you do Grant Cardone’s “What Could I Do to Make More Money Exercise?”

As Grant writes:

“When I do this I only look at income possibilities not how to cut expenses. I am not trying to get smaller, I am trying to expand. The question is anything to do with expansion and acquisition. How do I get in front of more people, help more people, collaborate with the right people and ultimately grow the company. This is NOT an exercise of how to make more money by cutting expenses.” [Read more…]

3D Printing, Stem Cell Manufacturing, Future Directions for iPSCs, and More

By

Hey, we’ve posted new content about stem cells and cord blood that I’m excited to share with you. Let me know what you think.

 

Without question, 3D printing is a transformative technology. It is now impacting a diverse range of industries, including medicine, science, technology, manufacturing, and defense. 3D printing is also impacting the stem cell industry, as recent weeks have seen “thaw and use” stem cell ink, 3D printing of iPSCs, and successful blood vessel creation. This article introduces current successes with 3D printing, including 3D printed kidneys and techniques that may speed up by 3D printing by 100, or possibly even 1000, times.

 

Cynata Therapeutics to Test Proprietary MSC Manufacturing Process in GvHD Clinical Trial
Cynata Therapeutics, a stem cell and regenerative medicine company listed on the Australian stock exchange (ASX: CYP), released major news by announcing that mesenchymal stem cells produced using its Cymerus™ manufacturing platform will be utilized in a Phase 1 clinical study involving patients with steroid-refractory GvHD. The Clinical Trial Company Ltd was identified as the contract research organization (CRO) that Cynata has engaged to conduct the study.

 

Where to Get Your Morning Stem Cell News? Top 15 Accounts to Follow on Twitter
In a July 2013 USA Today article, Rem Rieder discusses how Twitter “can function as a conveyor belt for first-rate journalism, bringing to your attention terrific material that you might otherwise never encounter”. He then goes on to point out that Twitter is a news pipeline for more than 200 million active users, often ‘breaking’ news before it’s actually news. In this article, you’ll learn the top 15 accounts to follow on Twitter to have breaking stem cell news delivered to your Twitter feed.

 

Future Directions for Induced Pluripotent Stem Cell Research, by an iPSC Scientist
The discovery that we can induce plasticity in formerly fully differentiated cells is one of the greatest inventions of the last decades. In this article, Kevin Bielec, a Scientist at RheinCell Therapeutics GmbH, explores a several aspects that should be considered as future directions for iPSC-related research and development. RheinCell is a Düsseldorf-based company that specializes in research-grade production and characterization of human induced pluripotent stem cells (iPSC).

 

Recently released, this 250-page global strategic report explores current and future opportunities for mesenchymal stem cells (MSCs). Importantly, it considers traditional market intelligence metrics (grant rates, patent rates, scientific publication rates, clinical trial rates, and more), as well as never released before social analytics (public user data from social media platforms, search engines, Google Trends, and more). Claim cutting-edge data that will improve your strategic decision-making, enhance your commercial strategies, and derive more revenue from MSC-related opportunities.

*Free Bonus: Claim this global strategic report by Fri, Nov. 20, 2015, and we will ship you a free hard copy of the report (value of $200). No code required if you act by Nov. 20, 2015.

 

Click here to view all recently released blog posts or here to view BioInformant’s global strategic reports for the stem cell and cord blood industry.  Be great!

[Read more…]

3 Bullet Thursday – Stem Cells for HIV, ESCs vs. iPSCs, and Twitter as a News Source

By

Stay alert to the latest and greatest on stem cells.  Enjoy this week’s “3 Bullet Thursday,” a weekly post that we do to update you on interesting and important events within the world of stem cells.

 

1. Wow, the world’s first clinical trial to treat HIV patients using umbilical cord blood transplants is set to start in Spain. Plans for the trial were announced last week at a haematology conference in Valencia by Spain’s National Organisation of Transplants (ONT).

 

2. Talk about a controversial topic! A new study published in Nature Biotechnology announces embryonic stem cells and induced pluripotent stem cells to be “equal.” More specifically, the authors state, “We conclude that hESCs and hiPSCs are molecularly and functionally equivalent.”

 

3. In a July 2013 USA Today article, Rem Rieder discusses how Twitter is a news pipeline for more than 200 million active users, often ‘breaking’ news before it’s actually news. Want to know where to get your morning stem cell news? These are the top 15 accounts breaking stem cell news on Twitter.

 

Happy Thursday!

 

Want to get this fun weekly update?  Join below and we’ll keep you in the loop, starting next week.

BioInformant's World-Class Clients